Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen

Science

Volumn 284, Issue 5418, 1999, Pages 1351-1354

  Wang, Rong Fu ^a   Wang, Xiang ^a   Atwood, Alicia C ^a   Topalian, Suzanne L ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE INSERTION; GENE MUTATION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; CLONING, MOLECULAR; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR1 ANTIGEN; HLA-DR4 ANTIGEN; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; POINT MUTATION; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TRIOSE-PHOSPHATE ISOMERASE;

EID: 0033591429     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.284.5418.1351     Document Type: Article

References (57)

1. S. Ostrand-Rosenberg, Curr. Opin. Immunol. 6, 722 (1994); D. M. Pardoll and S. L. Topalian, ibid. 10, 588 (1998).
2. S. Ostrand-Rosenberg, Curr. Opin. Immunol. 6, 722 (1994); D. M. Pardoll and S. L. Topalian, ibid. 10, 588 (1998).
3. J. D. Katz, C. Benoist, D. Mathis, Science 268, 1185 (1995); V. Kouskoff et al., Cell 87, 811 (1996); R. Tisch and H. McDevitt, ibid. 85, 291 (1996); A. O'Garra, L. Steinman, K. Gijbels, Curr. Opin. Immunol. 9, 872 (1997); C. A. Bona, S. Casares, T. D. Brumeanu, Immunol. Today 19, 126 (1998).
4. J. D. Katz, C. Benoist, D. Mathis, Science 268, 1185 (1995); V. Kouskoff et al., Cell 87, 811 (1996); R. Tisch and H. McDevitt, ibid. 85, 291 (1996); A. O'Garra, L. Steinman, K. Gijbels, Curr. Opin. Immunol. 9, 872 (1997); C. A. Bona, S. Casares, T. D. Brumeanu, Immunol. Today 19, 126 (1998).
5. J. D. Katz, C. Benoist, D. Mathis, Science 268, 1185 (1995); V. Kouskoff et al., Cell 87, 811 (1996); R. Tisch and H. McDevitt, ibid. 85, 291 (1996); A. O'Garra, L. Steinman, K. Gijbels, Curr. Opin. Immunol. 9, 872 (1997); C. A. Bona, S. Casares, T. D. Brumeanu, Immunol. Today 19, 126 (1998).
6. J. D. Katz, C. Benoist, D. Mathis, Science 268, 1185 (1995); V. Kouskoff et al., Cell 87, 811 (1996); R. Tisch and H. McDevitt, ibid. 85, 291 (1996); A. O'Garra, L. Steinman, K. Gijbels, Curr. Opin. Immunol. 9, 872 (1997); C. A. Bona, S. Casares, T. D. Brumeanu, Immunol. Today 19, 126 (1998).
7. J. D. Katz, C. Benoist, D. Mathis, Science 268, 1185 (1995); V. Kouskoff et al., Cell 87, 811 (1996); R. Tisch and H. McDevitt, ibid. 85, 291 (1996); A. O'Garra, L. Steinman, K. Gijbels, Curr. Opin. Immunol. 9, 872 (1997); C. A. Bona, S. Casares, T. D. Brumeanu, Immunol. Today 19, 126 (1998).
8. S. R. Riddell and P. D. Greenberg, Annu. Rev. Immunol. 13, 545 (1995); E. A. Walter et al., N. Engl. J. Med. 333, 1038 (1995); S. A. Kalams and B. D. Walker, J. Exp. Med. 188, 2199 (1999).
9. S. R. Riddell and P. D. Greenberg, Annu. Rev. Immunol. 13, 545 (1995); E. A. Walter et al., N. Engl. J. Med. 333, 1038 (1995); S. A. Kalams and B. D. Walker, J. Exp. Med. 188, 2199 (1999).
10. S. R. Riddell and P. D. Greenberg, Annu. Rev. Immunol. 13, 545 (1995); E. A. Walter et al., N. Engl. J. Med. 333, 1038 (1995); S. A. Kalams and B. D. Walker, J. Exp. Med. 188, 2199 (1999).
11. P. Cresswell, Annu. Rev. Immunol. 12, 259 (1994); R. N. Germain. Cell 76, 287 (1994).
12. P. Cresswell, Annu. Rev. Immunol. 12, 259 (1994); R. N. Germain. Cell 76, 287 (1994).
13. P. Cresswell, Cell 84, 505 (1996); B. Fineschi and J. Miller, Trends Biochem. Sci. 22, 377 (1997).
14. P. Cresswell, Cell 84, 505 (1996); B. Fineschi and J. Miller, Trends Biochem. Sci. 22, 377 (1997).
15. P. A. Monach, S. C. Meredith, C. T. Siegel, H. Schreiber, Immunity 2, 45 (1995); T. Halder et al., Cancer Res. 57, 3238 (1997).
16. P. A. Monach, S. C. Meredith, C. T. Siegel, H. Schreiber, Immunity 2, 45 (1995); T. Halder et al., Cancer Res. 57, 3238 (1997).
17. R. Pieper et al., J. Exp. Med. 189, 757 (1999).
18. S. L. Topalian et al., Proc. Natl. Acad. Sci. U.S.A. 91, 9461 (1994); S. L. Topalian et al., J. Exp. Med. 183, 1965 (1996).
19. S. L. Topalian et al., Proc. Natl. Acad. Sci. U.S.A. 91, 9461 (1994); S. L. Topalian et al., J. Exp. Med. 183, 1965 (1996).
20. HEK 293 cells were transected with plasmids encoding DRα, DRβ, Ii, DMA, and DMB individually. Transfectants were selected in media containing G418, hygromycin, and puromycin. Expression of human leukocyte AG DR (HLA-DR) was evaluated by fluorescence-activated cell sorting analysis with either monoclonal antibodies to HLA-DR1 or HLA-DR4 (One Lambda, Canoga Park, CA). Expression of DMA, DMB, and Ii was detected by protein immunoblot with antibodies to DMA (anti-DMA), anti-DMB, and anti-li.
21. S. P. Fling, B. Arp, D. Plous, Nature 368, 554 (1994); P. Morris et al., Ibid., p. 551; L. K. Denzin and P. Cresswell, Cell 82, 155 (1995); P. A. Roche, Immunity 3, 259 (1995).
22. S. P. Fling, B. Arp, D. Plous, Nature 368, 554 (1994); P. Morris et al., Ibid., p. 551; L. K. Denzin and P. Cresswell, Cell 82, 155 (1995); P. A. Roche, Immunity 3, 259 (1995).
23. S. P. Fling, B. Arp, D. Plous, Nature 368, 554 (1994); P. Morris et al., Ibid., p. 551; L. K. Denzin and P. Cresswell, Cell 82, 155 (1995); P. A. Roche, Immunity 3, 259 (1995).
24. S. P. Fling, B. Arp, D. Plous, Nature 368, 554 (1994); P. Morris et al., Ibid., p. 551; L. K. Denzin and P. Cresswell, Cell 82, 155 (1995); P. A. Roche, Immunity 3, 259 (1995).
25. The constructs pHG810, plHG812, plHG813, and plHG814 were made as follows. The Ii fragments (amino acids 1 to 60, 1 to 80, and 1 to 108) were generated by polymerase chain reaction amplification with specific sets of primers and cloned into the eukaryotic expression vector pcDNA3.1 (Invitrogen, San Diego, CA) to produce the pl60, pl80, and pl108 plasmids, respectively. A 400-base pair DNA fragment containing the HA(307-319) epitope was amplified from a plasmid encoding an influenza virus HA and was inserted into pl60, pl80, and pl108 to generate plH60, plH80, and plH108, respectively. A DNA fragment encoding enhanced green fluorescence protein (EGFP) from pEGFP-N3 (Clontech, Palo Alto, CA) was then fused in-frame to the COOH-terminus of the 1H fusion constructs. The resultant plasmids were named plHG812, plHG813, and plHG814, pHG810 was constructed in the same way except for omission of the Ii fragment.
26. Supplementary material is available at www.science. org/feature/data/987217.shl
27. R. F. Wang, X. Wang, A. C. Atwood, S. A. Rosenberg, unpublished data.
28. S. Sanderson, K. Frauwirth, N. Shastri, Proc. Natl, Acad. Scid. U.S.A. 92, 7217 (1995); N. Nakano, R. Rooke, C. Benoist, D. Mathis, Science 275, 678 (1997).
29. S. Sanderson, K. Frauwirth, N. Shastri, Proc. Natl, Acad. Scid. U.S.A. 92, 7217 (1995); N. Nakano, R. Rooke, C. Benoist, D. Mathis, Science 275, 678 (1997).
30. Total RNAs were extracted from 1558mel and 1359mel with Trizol reagent from GIBCO BRL (Gaithersburg, MD). Polyadenylated RNAs were purified from total RNA by using polyATract System (Pro-mega, Madison, WI) and converted to cDNA with a cDNA construction kit (GIBCO BRL) with an oligo-dT primer. The cDNA inserts were cloned into the expression vector pTSX. The cDNA libraries were electroporated into DH10B bacteria cells (GISCO BRL). Plasmid DNA pools were prepared from bacteria, each consisting of about 100 cDNA clones.
31. 5 cDNA clones were screened by expression in 293IMDR4 cells (17). Two positive pools were identified in the first screening. Individual DNA was prepared from about 800 Escherichia coli colonies transformed with the positive-pool DNA, and six positive cDNA clones were isolated by repeating the screening procedure.
32. DNA transfection with GM-CSF assays were performed as previously described [R. F. Wang, P. F. Robbins, Y. Kawakami, X. Q. Kang, S. A. Rosenberg, J. Exp. Med. 181, 799 (1995); R.-F. Wang et al., ibid. 184, 2207 (1996); R.-F. Wang et al., J. Immunol. 161, 3596 (1998)].
33. DNA transfection with GM-CSF assays were performed as previously described [R. F. Wang, P. F. Robbins, Y. Kawakami, X. Q. Kang, S. A. Rosenberg, J. Exp. Med. 181, 799 (1995); R.-F. Wang et al., ibid. 184, 2207 (1996); R.-F. Wang et al., J. Immunol. 161, 3596 (1998)].
34. DNA transfection with GM-CSF assays were performed as previously described [R. F. Wang, P. F. Robbins, Y. Kawakami, X. Q. Kang, S. A. Rosenberg, J. Exp. Med. 181, 799 (1995); R.-F. Wang et al., ibid. 184, 2207 (1996); R.-F. Wang et al., J. Immunol. 161, 3596 (1998)].
35. S. Tugendreich, M. S. Boguski, M. S. Seldin, P. Hieter, Proc. Natl. Acad. Sci. U.S.A. 90, 10031 (1993); P.-L. Chen et at., Cell Growth Differ. 6, 199 (1995); S. Tugendreich, J. Tomkiel, W. Earnshaw, P. Hieter, Cell 81, 261 (1995); R. W. King et al., ibid., p. 279.
36. S. Tugendreich, M. S. Boguski, M. S. Seldin, P. Hieter, Proc. Natl. Acad. Sci. U.S.A. 90, 10031 (1993); P.-L. Chen et at., Cell Growth Differ. 6, 199 (1995); S. Tugendreich, J. Tomkiel, W. Earnshaw, P. Hieter, Cell 81, 261 (1995); R. W. King et al., ibid., p. 279.
37. S. Tugendreich, M. S. Boguski, M. S. Seldin, P. Hieter, Proc. Natl. Acad. Sci. U.S.A. 90, 10031 (1993); P.-L. Chen et at., Cell Growth Differ. 6, 199 (1995); S. Tugendreich, J. Tomkiel, W. Earnshaw, P. Hieter, Cell 81, 261 (1995); R. W. King et al., ibid., p. 279.
38. S. Tugendreich, M. S. Boguski, M. S. Seldin, P. Hieter, Proc. Natl. Acad. Sci. U.S.A. 90, 10031 (1993); P.-L. Chen et at., Cell Growth Differ. 6, 199 (1995); S. Tugendreich, J. Tomkiel, W. Earnshaw, P. Hieter, Cell 81, 261 (1995); R. W. King et al., ibid., p. 279.
39. T. Wölfel et al., Science 269, 1281 (1995).
40. P. F. Robbins et al., J. Exp. Med. 183, 1185 (1996); B. Rubinfeld et al., Science 275, 1790 (1997).
41. P. F. Robbins et al., J. Exp. Med. 183, 1185 (1996); B. Rubinfeld et al., Science 275, 1790 (1997).
42. D. E. Brash et al., Proc. Natl. Acad. Sci. U.S.A. 88, 10124 (1991).
43. Peptides were synthesized by a solid-phase method with an automatic peptide synthesizer (Model AMS 422, Gilson, Worthington, OH). The masses of some peptides were confirmed by mass spectrometry, and peptides were purified by high-pressure liquid chromatography as needed to obtain purities greater than 98%.
44. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
45. H. G. Rammensee, T. Friede, S. Stevanovic, Immunogenetics 41, 178 (1995); S. Southwood et al., J. Immunol. 160, 3363 (1998).
46. H. G. Rammensee, T. Friede, S. Stevanovic, Immunogenetics 41, 178 (1995); S. Southwood et al., J. Immunol. 160, 3363 (1998).
47. Cell lysates were prepared by lysis buffer. Equal amounts of total protein were loaded for each sample and separated on a 4 to 16% SDS-polyacrylamide gel by electrophoresis (SDS-PAGE), The proteins were then blotted onto a nitrocellulose membrane and incubated with a murine antibody to human CDC27 (Transduction Lab) or a rabbit polydonal antibody to human CDC27. After incubation with an anti-mouse or anti-rabbit immunoglobulin G conjugated with horseradish peroxidase, protein was detected with the ECL system (Amersham).
48. B. E. Kemp and R. B. Pearson, Trends Biochem. Sci. 15, 342 (1990).
49. I. Verma, J. Stevenson, E. Schwarz, D. Van Antwerp, S. Miyamoto, Genes Dev. 9, 2723 (1995); A. Baldwin, Annu. Rev. Immunol. 14, 649 (1996).
50. I. Verma, J. Stevenson, E. Schwarz, D. Van Antwerp, S. Miyamoto, Genes Dev. 9, 2723 (1995); A. Baldwin, Annu. Rev. Immunol. 14, 649 (1996).
51. M. Enari et al., Nature 391, 43 (1998).
52. A. Hershko and A. Ciechanover, Annu. Rev. Biochem. 67, 425 (1998); A. Ciechanover, EMBO J. 17, 7151 (1998).
53. A. Hershko and A. Ciechanover, Annu. Rev. Biochem. 67, 425 (1998); A. Ciechanover, EMBO J. 17, 7151 (1998).
54. J. R. Knowles and W. J. Albery, Acc. Chem. Res. 10, 105 (1977); H. Ji et al., Electrophoresis 18, 605 (1997); K. S. Clauser et al., Proc. Natl. Acad. Sci. U.S.A. 92, 5072 (1995).
55. J. R. Knowles and W. J. Albery, Acc. Chem. Res. 10, 105 (1977); H. Ji et al., Electrophoresis 18, 605 (1997); K. S. Clauser et al., Proc. Natl. Acad. Sci. U.S.A. 92, 5072 (1995).
56. J. R. Knowles and W. J. Albery, Acc. Chem. Res. 10, 105 (1977); H. Ji et al., Electrophoresis 18, 605 (1997); K. S. Clauser et al., Proc. Natl. Acad. Sci. U.S.A. 92, 5072 (1995).
57. We thank J. Yannelli, J. R. Wunderlich, and the TIL lab for cell lines and reagents; M. Parkhurst and E. Fitzgerald for peptide synthesis; R. N. Germain for discussion and reading of the manuscript; E. Long for the plasmid containing human invariant chain cDNA; P. Cresswell for antibodies to DM and to Ii; C.-H. Chang for cDNA encoding DMA and DMB; J. Trowsdale for an antibody to DM; and P. Hieter for antibodies to CDC27 AND CDC16.